ER, That shows the title of the email and nothing
Post# of 148158
That shows the title of the email and nothing else. In no scenario would the FDA tell a congressman, “Yes, leronlimab is going to receive EUA,” and then also say, “Sure, share the pending EUA with random constituents (aka CYDY investors) over email.” That would be a SEC and ethics violation. I’ve been wrong in the past and I’ve admitted that, and will admit it if an EUA is announced tomorrow with a nod to Rep. Davis, but it seems unlikely for numerous reasons.